Wahner H W
Mayo Clin Proc. 1985 Dec;60(12):827-35. doi: 10.1016/s0025-6196(12)64788-0.
In the management of patients with metabolic bone disease, nuclear medicine laboratories offer two nontraumatic procedures of potential clinical importance: bone mineral measurements and bone scintigraphy. Bone mineral measurements from the radius, lumbar spine, and hip obtained with use of absorptiometry or computed tomography can be used to predict the risk of fracture at these skeletal sites, can determine the severity of bone loss for the assessment of a benefit-versus-risk ratio on which appropriate therapy can be based, and can substantiate the effectiveness of therapy over time. Bone scintigraphy with use of labeled diphosphonate allows assessment of focal and, in defined circumstances, of total skeletal bone turnover in patients with normal kidney function. Both of these techniques have been used successfully in studies of population groups for the evaluation of trends. Their application to the management of individual patients is currently being evaluated.
在代谢性骨病患者的管理中，核医学实验室提供两种具有潜在临床重要性的非创伤性检查：骨矿物质测量和骨闪烁显像。使用吸收测定法或计算机断层扫描获得的桡骨、腰椎和髋部的骨矿物质测量结果可用于预测这些骨骼部位的骨折风险，可确定骨质流失的严重程度以评估可据此进行适当治疗的获益风险比，并可证实治疗随时间推移的有效性。使用标记二膦酸盐的骨闪烁显像可评估肾功能正常患者的局灶性以及在特定情况下的全身骨骼骨转换。这两种技术均已成功用于人群研究以评估趋势。目前正在评估它们在个体患者管理中的应用。
